Navigation Links
Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614

PALO ALTO, Calif., July 29, 2013 /PRNewswire/ --  Signature Therapeutics, Inc., a development-stage biopharmaceutical company, announced today that it has received no-cost access to contractor resources through the National Center for Advancing Translational Sciences' Bridging Interventional Development Gaps (BrIDGs) program (part of the NIH) to support development of its extended-release, abuse-deterrent oxycodone, PF614 – a novel, inactive prodrug formulation that must be digested to achieve therapeutic benefit.  NIH's National Institute on Drug Abuse is providing funding directly to BrIDGs to support the project, which includes scale-up synthesis, drug product packaging, pharmacokinetic analysis and IND-enabling toxicology studies.


Wes Sterman, President and CEO of Signature Therapeutics, commented, "We are grateful to the staff of NIDA and NCATS that saw the value of our abuse-deterrent prodrug technology and which made the decision to provide contractor resources to further our work.  Their support helps validate the importance of the prodrug technology approach in the field of abuse-deterrent opioid drugs, and the potential of the technology to greatly impact the public health crisis of prescription drug abuse.  We look forward to the continued development of PF614, and anticipate the filing of a US IND in the first half of 2014."

About Prescription Drug Abuse

Abuse of prescription drugs is the fastest growing drug problem according to the US Office of National Drug Control Policy (ONDCP).1   The Centers for Disease Control (CDC) has characterized this problem as an epidemic in the United States.2  More Americans die from overdose of prescription pain killers than from abuse of heroin and cocaine combined, reaching approximately 17,000 deaths per year.3,4  The healthcare costs of prescription drug abuse exceed $72 billion per year in the US.5 

About PF614

PF614 is a prodrug of the opioid drug oxycodone that is designed to create substantial hurdles to both oral and non-oral routes of abuse.  Typical methods of abuse of prescription opioid drugs include inhaling or injecting crushed pills or chewing intact pills.  Current efforts to thwart these modes of abuse, involving improved tablet-formulation technology to make tablets harder to crush and the opioid drug harder to remove from the tablet, provide some increased level of abuse-resistance.  However, Signature Therapeutics' prodrug technology involves creating new molecules that provide very high levels of abuse-resistance based upon the design of the molecules themselves.  PF614 is a novel molecule that is designed to release the opioid drug oxycodone only upon its digestion in the patient's small bowel.  It is essentially inert when inhaled or injected, resistant to chemical manipulation outside of the body, and completely resistant to release of oxycodone upon chewing. 

About Signature Therapeutics

Signature Therapeutics, Inc., is a development-stage biopharmaceutical company located in Palo Alto, California.  The Company focuses on the discovery and development of a portfolio of novel chemical entities for the potential treatment of neurological disorders. 

Signature Therapeutics Contact:
Wes Sterman, CEO
phone:  650-331-4001

1.  Epidemic: Responding to America's Prescription Drug Abuse Crisis, OFFICE OF NATIONAL DRUG CONTROL POLICY (2011), available at

2.  Leonard Paulozzi, et al., CDC Grand Rounds: Prescription Drug Overdoses—A U.S. Epidemic, CENTERS FOR DISEASE CONTROL AND PREVENTION, Jan. 13, 2012, available at

3.  LEONARD PAULOZZI, supra Note 2.

4.  Press Release, Centers for Disease Control and Prevention, Opioids Drive Continued Increase in Drug Overdose Deaths (Feb. 20, 2013), available at

5.  See Prescription Drug Abuse and Overdose: Public Health Perspective, CENTERS FOR DISEASE CONTROL AND PREVENTION, Oct. 24, 2012, available at

SOURCE Signature Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Wacoms New DTU-1031 Provides Paperless Electronic Signature Solution for Businesses
2. CLAAD Lauds Signature Therapeutics R&D Efforts To Reduce Prescription Drug Abuse
3. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
8. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
9. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
10. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
11. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015  EndoChoice Holdings, Inc. ... third quarter 2015 financial results on Thursday, November 5, ... . --> . ... Thursday, November 5, 2015 at 9:00 a.m. ET to ... for domestic callers and (412) 317-5469 for international callers. ...
(Date:10/13/2015)... , Oct. 13, 2015   Rosa & ... firm in Quantitative Systems Pharmacology (QSP)/ PhysioPD™ , today ... will lead a workshop at the QSP Congress ... Boston, MA.  The conference focuses ... drug development.  Dr. Friedrich,s workshop is entitled "Using Mechanistic ...
(Date:10/13/2015)... 13, 2015  Yesterday Congresswoman Renee Ellmers ... manufacturing site located in Holly Springs, NC ... produced Flucelvax ® (Influenza Vaccine) using cell-culture technology, a ... start-up and is not reliant on chicken eggs. 1,2 ... influenza vaccines business of Novartis AG in the US, ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 2015 , ... Tempe Dental Care, a leading Tempe dentists’ office, celebrates offering ... dentistry for more than 5 years. A leading cause of emergency room visits, ... treatment is not timely. , Sedation dentistry provides an anxiety-free dental ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Local Gold’s ... Gold’s Gym International Conference on August 26. Berry, who owns and operates Gold's ... for the fastest growing Gold’s Gyms in the United States. A brand leader in ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... Bill Saye as the newest professional to introduce the latest development, ThermiVa® temperature ... recognized as a leading professional in Obstetrics and Gynecology and a pioneer in ...
(Date:10/13/2015)... ... 13, 2015 , ... In an ongoing effort to provide ... Southlake, Texas, child development and pediatric therapy center, is working with TRICARE to ... their options for receiving this kind of care for affected children. Because of ...
(Date:10/13/2015)... ... ... Just under three months ago, eMarketing Concepts forever changed the ... offering all of their services for just a buck in the first month. The ... calls from interested buyers. As a genuine one-stop-shop for internet marketing, EMC has cornered ...
Breaking Medicine News(10 mins):